JPMorgan Chase & Co. acquired 3.49 million shares of BEONE MEDICINES (06160) via an off-exchange derivative transaction on September 28, 2026, at an average of HKD 217.8227 per share, involving about HKD 759.41 million. The transaction was effected through equity derivatives, not on the SEHK open market, therefore not a direct secondary-market dealing.
Prior to the acquisition, JPMorgan Chase & Co.'s long position in BEONE MEDICINES was 139.97 million shares, representing 9.8%; following the acquisition, the holding changed to 143.45 million shares, with the long position ratio rising to 10.05%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments